| Univariate analysis |
Hazard ratio (95% CI) | p-value |
Age >60 yrs | 12.5 (1.5–104.0) | 0.02 |
Male sex | 0.7 (0.2–2.5) | 0.5 |
ECOG | | |
0 | 1 | |
1 | 20.3 (2.1–190.4) | 0.008 |
2–3 | 38.6 (4–374) | 0.002 |
Diagnosis delay (per 1 month increase) | 1.0 (0.99–1.02) | 0.8 |
Extrapulmonary location | 2.2 (0.6–8.4) | 0.2 |
Gastric | 1.8 (0.4–7.8) | 0.4 |
Nodal | 6.0 (0.6–58.8) | 0.1 |
Medullar | | 0.52# |
Pulmonary extension | | |
Mediastinal adenopathy | 2 (0.2–17.7) | 0.5 |
Bilateral involvement | 1.7 (0.4–6.4) | 0.4 |
Pleural effusion | 5.4 (0.9–30.6) | 0.1 |
Treatment | | |
Chlorambucil | 1 | |
Cyclophosphamide based chemotherapy | 0.9 (0.1–6.6) | 0.9 |
Anthracyclin- or fludarabine-based chemotherapy | 2.6 (0.4–6) | 0.3 |
Local therapy | 0.2 (0.02–2.7) | 0.2 |
Abstention | 4.6 (0.4–54) | 0.2 |